TABLE 3.
Tumor Characteristics by Stage Change (Upstage, Downstage, or no Change) from the 7th to the 8th Edition of the AJCC Staging Manual
| All Patients (N = 493,854) |
Downstage (n = 146,845) (29.7%) |
No Change (n = 313,375) (63.4%) |
Upstage (n = 33,634) (6.8%) |
P | |
|---|---|---|---|---|---|
| Histology | |||||
| Ductal | 438,334 | 123,014 (28.1%) | 283,353 (64.6%) | 31,967 (7.3%) | <0.0001 |
| Lobular | 51,334 | 23,464 (45.7%) | 27,564 (53.7%) | 306 (0.6%) | |
| Other | 4,186 | 367 (8.8%) | 2,458 (58.7%) | 1,361 (32.5%) | |
| Oncotype Dx score | |||||
| 0–10 | 24,759 | 8088 (32.7%) | 16,639 (67.2%) | 32 (0.1%) | <0.0001 |
| 11–100 | 84,223 | 26,028 (30.9%) | 57,723 (68.5%) | 472 (0.6%) | |
| Not available | 384,872 | 112,729 (29.3%) | 239,013 (62.1%) | 33,130 (8.6%) | |
| HR status | |||||
| HR+ | 424,016 | 145,772 (34.4%) | 278,077 (65.6%) | 167 (0%) | <0.0001 |
| HR− | 69,838 | 1073 (1.5%) | 35,298 (50.5%) | 33,467 (47.9%) | |
| Grade | |||||
| 1 | 126,024 | 28,590 (22.7%) | 97,434 (77.3%) | 0 (0%) | <0.0001 |
| 2 | 223,832 | 78,470 (35.1%) | 138,761 (62%) | 6601 (2.9%) | |
| 3 | 143,998 | 39,785 (27.6%) | 77,180 (53.6%) | 27,033 (18.8%) | |
| ER status | |||||
| ER+ | 419,706 | 145,589 (34.7%) | 273,972 (65.3%) | 145 (0%) | <0.0001 |
| ER− | 74,148 | 1256 (1.7%) | 39,403 (53.1%) | 33,489 (45.2%) | |
| PR status | |||||
| PR+ | 373,896 | 141,715 (37.9%) | 232,159 (62.1%) | 22 (0%) | <0.0001 |
| PR− | 119,958 | 5130 (4.3%) | 81,216 (67.7%) | 33,612 (28%) | |
| HER2 status | |||||
| HER2 equivocal* | 10,360 | 3532 (34.1%) | 6167 (59.5%) | 661 (6.4%) | <0.0001 |
| HER2+ | 60,155 | 17,659 (29.4%) | 42,496 (70.6%) | 0 (0%) | |
| HER2− | 423,339 | 125,654 (29.7%) | 264,712 (62.5%) | 32,973 (7.8%) | |
Percentages are based on the intrarow frequency and total for each individual variable. LN, lymph nodes.
*
Included as HER2− in later analyses.